IN8bio: Newly Granted Global Patents

 

• Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs).
   
• Broadens IN8bio’s foundational intellectual property (IP) for its proprietary DeltEx DRI platform which covers the use of any genetic modification that conveys chemotherapy resistance in gamma-delta T cells, as well as natural killer (NK) cells.
   
• IN8bio now holds 19 total granted U.S. and international patents, and numerous pending patent applications.

https://www.biospace.com/article/releases/in8bio-strengthens-intellectual-property-portfolio-with-newly-granted-global-patents/